What happens to cardiovascular risk when you stop GLP-1 therapy
The heart-risk reduction tends to track with the metabolic improvements — and those drift back when therapy stops.
TL;DR
- Stopping GLP-1 therapy is usually followed by weight regain and a return of blood pressure and metabolic markers toward baseline.
- Cardiovascular benefit observed during therapy tends to fade as those markers drift back.
- The published trials describe this as the typical pattern, not a guaranteed outcome.
What it is
GLP-1 receptor agonists (in plain English: medications that mimic the body’s natural fullness-and-glucose-control hormone) — including semaglutide and tirzepatide — produce sustained changes in weight, blood pressure, and blood sugar while patients stay on therapy. The clinical question this post answers is what tends to happen to those changes — and the cardiovascular benefit that comes with them — when the medication stops. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026).
How it works
Picture a thermostat holding a room at a steady temperature. The thermostat is doing real work — every minute — to keep the room there. Turn the thermostat off and the room slowly returns to whatever the outside conditions dictate. GLP-1 therapy works the same way. The medication produces a daily fullness signal, slows stomach emptying, and steadies blood sugar. Stop the medication, and the daily signal stops. Appetite returns, stomach emptying returns to baseline, and the metabolic numbers track upward again.
Who asks about it
People come to this question when they are deciding whether GLP-1 therapy is a “fix and finish” or a long-term tool. The honest framing in the published literature is closer to long-term tool than one-and-done. Stopping is possible — many patients do — but the heart-risk benefits described in cardiovascular outcome trials are tied to ongoing therapy, not to having taken it once.
What the research says
The STEP-4 extension trial reported that patients who stopped semaglutide regained on average about two-thirds of the weight they had lost, with corresponding return of blood pressure and metabolic markers — while those who continued maintained the improvements (Rubino et al., JAMA, 2021). The SELECT cardiovascular outcomes trial of semaglutide in patients with overweight and pre-existing cardiovascular disease reported a roughly 20% reduction in major cardiovascular events during ongoing therapy (Lincoff et al., NEJM, 2023). The implication is that benefit tracks with therapy continuation.
What to know before considering it
Stopping GLP-1 therapy is a clinical decision, not a casual one. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Tapering, monitoring, and a plan for diet and physical activity should be discussed with the prescribing clinician. Compounded GLP-1 prescribing requires a valid prescription and a licensed clinician evaluation.
The Halftime POV
The cleanest read of the data: GLP-1 therapy is doing the work, the benefit reflects the therapy, and stopping returns the body toward baseline. That does not make stopping wrong — it makes the conversation a real one with the prescribing clinician about goals, duration, and what comes next.
Related reading:
- GLP-1 rebound: why weight can return when therapy stops
- GLP-1: what this gut hormone actually does
- GLP-1 side effects in the published literature
FAQ
Q: What happens to heart risk when you stop GLP-1? A: In published trials, weight, blood pressure, and metabolic markers tend to drift back toward baseline after stopping. Cardiovascular benefit fades along with the metabolic improvements.
Q: Does blood pressure go back up after stopping semaglutide? A: Often partially, yes. The STEP-4 extension study reported blood pressure and weight regain in patients who stopped semaglutide, while those who continued maintained the improvements.
Q: Is compounded GLP-1 FDA-approved? A: No. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
